The announcement of a class action lawsuit against Kyverna Therapeutics is likely to negatively impact its stock price in the short term as it raises concerns about potential financial liabilities and investor sentiment. The notification to shareholders about potential recovery options under federal securities laws further emphasizes the seriousness of the legal issue.